We are live on ! Find out more
BIOL

Biolase, Inc.

Delisted

BIOL was delisted on the 18th of June, 2024.

15 hedge funds and large institutions have $14.9M invested in Biolase, Inc. in 2018 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

72% more capital invested

Capital invested by funds: $8.65M → $14.9M (+$6.21M)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

17% less funds holding

Funds holding: 1815 (-3)

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

Holders
15
Holders Change
-3
Holders Change %
-16.67%
% of All Funds
0.34%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
2
Increased
4
Reduced
4
Closed
5
Calls
Puts
Net Calls
Net Calls Change

BIOL Hedge Fund Activity: Q3 2018 in Review

15 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Biolase, Inc. (BIOL) for Q3 2018, worth a combined $14.9M — up 72% from $8.65M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of BIOL and 2 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 4 added.

The largest buyer was Trellus Management Company, opening a new position worth an estimated $180K. The largest seller was Birchview Capital, cutting an estimated $152K.

  • 15 institutional investors held Biolase, Inc. (BIOL) as of Q3 2018, down from 18 in Q2 2018.
  • Funds reported $14.9M of Biolase, Inc. stock for Q3 2018, up 72% quarter-over-quarter.
  • 2 funds opened new Biolase, Inc. positions in Q3 2018 and 5 closed out, a net change of -3 holders.
  • The largest Biolase, Inc. buyer in Q3 2018 was Trellus Management Company, an estimated $180K added.
  • The largest Biolase, Inc. seller in Q3 2018 was Birchview Capital, an estimated $152K sold.

Based on aggregated 13F filings for Q3 2018.